Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618639 | 0.95 | POLB (0.37) | POLBALDH1A1PTGES | |
| SCHEMBL930036 | 0.89 | KDM4D (0.34) | POLBALDH1A1PTGESKMT2AKDM4D | |
| SCHEMBL17093613 | 0.78 | KDM4A (0.39) | ALDH1A1KMT2A | |
| SCHEMBL2520169 | 0.77 | — | — | |
| SCHEMBL790160 | 0.75 | MEN1 (0.33) | KMT2A | |
| SCHEMBL17093961 | 0.75 | TMEM97 (0.32) | ALDH1A1KMT2A | |
| SCHEMBL360638 | 0.74 | GPR84 (0.34) | KMT2A | |
| SCHEMBL18992802 | 0.73 | KDM4A (0.41) | ALDH1A1KMT2A | |
| SCHEMBL11060568 | 0.72 | FFAR1 (0.38) | ALDH1A1KMT2A | |
| SCHEMBL15263236 | 0.72 | FFAR1 (0.38) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-03-08 | — | — | US | disclosed |
| US-8088803-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2012-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | POLB 2730/4885ALDH1A1 157/4885PTGES 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.